Author

Debra A. Marshall

Observed name: Debra Marshall

Institution: ARCA Biopharma (United States)

Observed institutions: Henry M. Jackson Foundation, National Institutes of Health, University of California, Los Angeles, Duke University, Walter Reed National Military Medical Center, ARCA Biopharma (United States), Duke Clinical Research Institute

ORCID: 0000-0002-2897-7759

Observed ORCID: 0000-0002-2897-7759

OpenAlex ID: A5103023838

Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population

2019 · Jonathan P. Piccini, William T. Abraham, et al. · JACC Heart Failure · 36

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype

2021 · Jonathan P. Piccini, Christopher Dufton, et al. · Circulation Arrhythmia and Electrophysiology · 15

The role of exercise in modulating the impact of an ultralow-fat diet on serum lipids and apolipoproteins in patients with or at risk for coronary artery disease

2006 · Debra A. Marshall, Marina N. Vernalis, et al. · American Heart Journal · 15

Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial

2023 · Connie N. Hess, Judith Hsia, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 13

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial

2022 · Connie N. Hess, Warren H. Capell, et al. · American Heart Journal · 11

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial

2017 · Jonathan P. Piccini, Stuart J. Connolly, et al. · American Heart Journal · 11

Performance of adult cardiac catheterization: Nonphysicians should not function as independent operators?A position statement

1999 · Debra Marshall, Charles E. Chambers, et al. · Catheterization and Cardiovascular Interventions · 8

Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

2021 · William T. Abraham, Jonathan P. Piccini, et al. · Heart Rhythm O2 · 5

Abstract 113: Novel Tissue Factor Inhibition For Thromboprophylaxis In COVID-19: Primary Results Of The ASPEN-COVID-19 Phase 2b Randomized Trial

2022 · Connie N Hess, Mark R Nehler, et al. · Arteriosclerosis Thrombosis and Vascular Biology

Works count: 9

Citation count: 114

H-index: 7

I10-index: 6